Prevention and treatment of amyloidogenic disease
AssigneeNeuralab Limited
InventorDale B. Schenk
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide or an antibody thereto.
Claims120
A method of therapeutically treating a disease characterized by an amyloid deposit of Aβ in a patient having the disease, comprising:
- administering an effective dose of a polypeptide comprising an immunogenic fragment of Aβ (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the Aβ fragment, the adjuvant enhancing the immune response to the Aβ fragment, and thereby therapeutically treat the disease in the patient.
The method of claim l, wherein the disease is Alzheimer's disease.
A method of therapeutically treating a disease characterized by an amyloid deposit of Aβ in a patient having the disease, comprising:
- administering an immunogenic fragment of Aβ peptide (SEQ ID NO:1) in a regime effective to induce an immune response comprising antibodies to the Aβ fragment and thereby therapeutically treat the disease in the patient, wherein the dose of the Aβ fragment administered to the patient at least 50 μg.
A method of therapeutically treating a disease characterized by an amyloid deposit of Aβ in a patient, comprising:
- administering an Aβ fragment (SEQ ID NO:1) in a regime effective to induce an immune response comprising antibodies to the Aβ fragment and thereby therapeutically treat the disease in the patient;
- and monitoring the patient for the immune response, wherein the monitoring comprises detecting antibodies having Aβ fragment binding specificity.
A method of prophylactically a disease characterized by an amyloid deposit of Aβ in a patient susceptible to the disease, comprising:
- administering an effective dose of a polypeptide comprising an immunogenic fragment of Aβ (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the Aβ fragment, the adjuvant enhancing the immune response to the Aβ fragment, and thereby prophylactically treat the disease in the patient.
A method of prophylactically treating a disease characterized by an amyloid deposit of Aβ in a patient, comprising:
- administering an immunogenic fragment of Aβ peptide (SEQ ID NO:1) in a regime effective to induce an immune response comprising antibodies to the Aβ fragment and thereby prophylactically treat the disease in the patient, wherein the dose of the Aβ fragment administered to the patient at least 50 μg.
A method of prophylactically treating a disease characterized by an amyloid deposit of Aβ in a patient susceptible to the disease, comprising:
- administering an Aβ fragment (SEQ ID NO:1) in a regime effective to induce an immune response comprising antibodies to the Aβ fragment and thereby prophylactically or therapeutically treat the disease in the patient;
- and monitoring the patient for the immune response, wherein the monitoring comprises detecting antibodies having Aβ fragment binding specificity.
A pharmaceutical composition comprising an immunogenic fragment of Aβ (SEQ ID NO:1) and a pharmaceutically acceptable adjuvant effective to induce an immune response comprising antibodies to the Aβ fragment, wherein the adjuvant enhances the immune to the Aβ fragment.
Dependencies are inferred from the claim text.